P1048: Vedolizumab in Indian patients with Inflammatory Bowel Disease: Final results from a prospective, multicentre, open-label, phase 4 studyECCO'25Year: 2025
Authors: Kabrawala, M.(1);Banerjee, R.(2)*;Ahuja, V.(3);Anumula, K.(4);Bhardwaj, V.(5);Dalal, A.(6);Ramesh Kumar, B.(7);Mukewar, S.(8);Sood, A.(9);Mohan Prasad, V.G.(10);Arora, S.(11);Bahuguna, G.(11);
(1)Surat Institute of Digestive Science- SIDS Hospital, Department of Gastroenterology, Surat, India;(2)Asian Institute of Gastroenterology, IBD Centre, Hyderabad, India;(3)All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India;(4)Government General Hospital, Department of Gastroenterology, Guntur, India;(5)Dr. Ram Manohar Lohia Hospital, Department of Gastroenterology, New Delhi, India;(6)Maulana Azad Medical College & Associated G B Pant Hospital, Department of Gastroenterology, New Delhi, India;(7)Osmania Medical College & General Hospital, Department of Gastroenterology, Hyderabad, India;(8)Midas Multi-Specialty Hospital, Department of Gastroenterology, Nagpur, India;(9)Dayanand Medical College and Hospital, Department of Gastroenterology, Ludhiana, India;(10)VGM Hospital, Institute of Gastroenterology, Coimbatore, India;(11)Takeda Biopharmaceuticals India Private Limited, Medical affairs, Gurgaon, India;
1. Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. Intest Res. 2017 Jan;15(1):138-141. doi: 10.5217/ir.2017.15.1.138
2. Ooi CJ, Hilmi IN, Kim HJ, et al. Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intest Res. 2021;19(1):71-82. doi:10.5217/ir.2019.09159.
3. Singh H, Grewal N, Arora E, Kumar H, Kakkar AK. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016;7(1):4-9. doi:10.4103/0976-9668.175016.
P1049: Intestinal ultrasound for assessment of steroid-refractory disease in patients hospitalized due to Acute Severe ColitisECCO'25Year: 2025
Authors: Kornowski Cohen, M.(1)*;Lev Kolnik, R.(1);Avni, I.(1);Snir, Y.(1);Broitman, Y.(1);Sharar Fischler, T.(1);Yanai, H.(1);Dotan, I.(1);Ollech, J.(1);Banai Eran, H.(1);
(1)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;
1. Allocca M, Filippi E, et al. Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European Gastroenterol J. 2021 May;9(4):438-442.
2. Javier P Gisbert, María José García, et al. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review. Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023: 972–994
3. Piazza O Sed N, Noviello D, et al. Superior predictive value of transmural over endoscopic severity for colectomy risk in ulcerative colitis: a multicentre prospective cohort study. J Crohns Colitis. 2024 Feb 26;18(2):291-299.
4. Adams A, Gupta V, et al. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut. 2023 Mar;72(3):433-442.
P1050: Development of a patient-centred dashboard for routine IBD monitoringECCO'25Year: 2025
Authors: Fierens, L.(1)*;Hedin, C.R.(2,3);Novacek, G.(4);Julsgaard, M.(5,6);Gross, E.(7);Arijs, I.(8);Sander, C.(9);Vakouftsi, V.R.(10);Koenders, J.(11);Vanhaverbeke, M.(1);Stamm, T.(12,13);Ferrante, M.(1,14);
(1)KU Leuven, Translational Research in Gastrointestinal Disorders- Department of Chronic Diseases and Metabolism CHROMETA, Leuven, Belgium;(2)Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden;(3)Karolinska University Hospital, Gastroenterology unit - Department of Gastroenterology- Dermatovenereology and Rheumatology, Stockholm, Sweden;(4)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;(5)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(6)Aarhus University, Institute of Clinical Medicine- Health, Aarhus, Denmark;(7)Österreichische Morbus Crohn / Colitis ulcerosa Vereinigung ÖMCCV, Österreichische Morbus Crohn / Colitis ulcerosa Vereinigung ÖMCCV, Vienna, Austria;(8)Belgian IBD Research and Development BIRD, Belgian IBD Research and Development BIRD, Zaventem, Belgium;(9)Deutsche Morbus Crohn/Colitis ulcerosa Vereinigung DCCV e.V., Referat Wissenschaft, Berlin, Germany;(10)Hellenic Society of Crohn’s disease and ulcerative colitis patients HELLESCC, Hellenic Society of Crohn’s disease and ulcerative colitis patients HELLESCC, Athens, Greece;(11)Takeda Pharmaceuticals International AG, Health Data partnerships / New Product Planning Centraal & Oost Europa, Hoofddorp, The Netherlands;(12)Medical University of Vienna, Institute for Outcomes Research- Center for Medical Data Science, Vienna, Austria;(13)Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria;(14)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
1) Fierens L, Carney N, Novacek G, van der Woude CJ, Siegmund B, Casellas F, Borruel N, Huberts AS, Sonnenberg E, Gerold N, Primas C, Hedin CRH, Stamm T, Julsgaard M, Fiorino G, Radice S, Zini MLL, Gross E, Sander C, Arijs I, Vakouftsi VR, Koltai T, Health Outcomes Observatory H O Patient Advisory Board For Inflammatory Bowel Diseases, Health Outcomes Observatory H O Steering Committee, Charlafti I, Ferrante M. A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process. J Crohns Colitis. 2024 Oct 15;18(10):1583-1595. doi: 10.1093/ecco-jcc/jjad195.
2) https://health-outcomes-observatory.eu/h2o-insights-center/
P1053: Clostridioides difficile Infection in Admitted patients with Ulcerative Colitis: Analysis of 23 Years through Propensity Score MatchingECCO'25Year: 2025
Authors: Alañón, P.(1);Carrillo, B.(1);Benítez, J.M.(1);Soto, P.(1);Marín Pedrosa, S.(1);Iglesias-Flores, E.(1);Gros, B.(2)*;
(1)Reina Sofía University Hospital, Gastroenterology and Hepatology, Cordoba, Spain;(2)Reina Sofía University Hospital. IMIBIC. University of Cordoba, Department of Gastroenterology, Córdoba, Spain;
P1054: Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world studyECCO'25Year: 2025
Authors: MocciMD FRCP, G.(1)*;Costa, F.(2);Ceccarelli, L.(2);Savarino, E.(3);Mucherino, C.(4);Marzo, M.(5);Scaldaferri, F.(6);Napolitano, D.(7);Pugliese, D.(8);Gravina, A.G.(9);Pellegrino, R.(10);Spagnuolo, R.(11);Cuomo, A.(12);Maconi, G.(13);Bertani, L.(14);Bodini, G.(15);Orrù, G.(16);Piergallini, S.(17);Scarcelli, A.(18);Capone, P.(19);Cortellini, F.(20);Rodinò, S.(21);Vespere, G.(22);Gaiani, F.(23);Pagnini, C.(24);Graziani, G.(24);Allegretta, L.(25);Ferronato, A.(26);Ribaldone, D.G.(27);Aragona, G.(28);Forti, G.(29);Di Fonzo, M.(30);Iacopini, F.(30);Pica, R.(31);Onidi, M.F.(1);Usai Satta, P.(32);Elisei, W.(33);Picchio, M.(34);Papa, A.(35);Tursi, A.(36);
(1)Gastroenterology Unit- ARNAS G. Brotzu, Medicine, Cagliari, Italy;(2)IBD Unit- Pisa University Hospital, General Surgery and Gastroenterology, Pisa, Italy;(3)Gastroenterology Unit, Azienda Ospedale-Università di Padova AOUP-, Padua, Italy;(4)Division of Gastroenterology, Azienda Ospedaliera “S. Anna e S. Sebastiano”, Caserta, Italy;(5)Division of Gastroenterology, “Veris-Delli Ponti” Hospital, Scorrano LE, Italy;(6)Digestive Diseases Centre CEMAD, Department of Medical and Surgical Sciences- Policlinico Universitario “A. Gemelli” Foundation- IRCCS- Catholic University- School of Medicine, Rome, Italy;(7)Digestive Diseases Centre CEMAD, Department of Medical and Surgical Sciences- Policlinico Universitario “A. Gemelli” Foundation- IRCCS, Rome, Italy;(8)Digestive Diseases Centre CEMAD, Department of Medical and Surgical Sciences- Policlinico Universitario “A. Gemelli” Foundation- IRCCS. Catholic University- School of Medicine- Rome, Rome, Italy;(9)University of Campania "Luigi Vanvitelli", Department of Precision Medicine- Hepatogastroenterology and Digestive Endoscopy Unit- University of Campania "Luigi Vanvitelli", Napoli, Italy;(10)University of Campania "Luigi Vanvitelli", Department of Precision Medicine- Hepatogastroenterology and Digestive Endoscopy Unit, Naples, Italy;(11)University of Catanzaro, Department of Health Science, Catanzaro, Italy;(12)“Umberto I” Hospital, Division of Gastroenterology, Nocera Inferiore SA, Italy;(13)Gastroenterology Unit, Department Biomedical and Clinical Sciences- “L. Sacco” University Hospital, Milano, Italy;(14)“Felice Lotti” Hospital- Azienda USL Toscana Nord Ovest- Pontedera PI, Division of Gastroenterology, Pontedera PI, Italy;(15)Division of Gastroenterology- IRCCS "San Martino" Hospital- University of Genoa, Department of Internal Medicine and Medical Specialties, Genoa, Italy;(16)Gastroenterology, Department of Medical sciences and public health- University of Cagliari, Cagliari CA, Italy;(17)IBD Unit- “A. Murri” Hospital, Division of Gastroenterology, Fermo, Italy;(18)“San Salvatore” Hospital, Division of Gastroenterology, Pesaro, Italy;(19)“T. Maresca” Hospital- Torre del Greco NA, Division of Gastroenterology, Torre del Greco NA, Italy;(20)“Infermi” Hospital, Division of Gastroenterology, Rimini, Italy;(21)Division of Gastroenterology- “Ciaccio-Pugliese” Hospital, Division of Gastroenterology- “Ciaccio-Pugliese” Hospital, Catanzaro, Italy;(22)Division of Gastroenterology- “Ospedale del Mare”- ASL Na1, Division of Gastroenterology- “Ospedale del Mare”- ASL Na1, Naples, Italy;(23)Gastroenterology and Endoscopy Unit, Department of Medicine and Surgery- University of Parma, Parma, Italy;(24)“S. Giovanni - Addolorata” Hospital, Division of Gastroenterology, Rome, Italy;(25)“Santa Caterina Novella” Hospital, Division of Gastroenterology, Galatina LE, Italy;(26)Digestive Endoscopy Unit, ULSS7 Pedemontana, Santorso VI, Italy;(27)Division of Gastroenterology- University of Turin- IBD Unit- "A.O.U. Citta della Salute e della Scienza di Torino", Department of Medical Sciences, Turin, Italy;(28)“Guglielmo da Saliceto" Hospital, Division of Gastroenterology, Piacenza, Italy;(29)“S. Maria Goretti” Hospital, Division of Digestive Endoscopy, Latina, Italy;(30)“Ospedale dei Castelli”- Ariccia Roma, Division of Gastroenterology, Ariccia Roma, Italy;(31)IBD Unit- “S. Pertini” Hospital, Division of Gastroenterology, Rome, Italy;(32)Gastroenterology Unit- ARNAS G. Brotzu, Medicine, Cagliari CA, Italy;(33)A.O. “S. Camillo-Folanini”, Division of Gastroenterology, Rome, Italy;(34)“P. Colombo” Hospital- ASL Roma 6- Velletri Roma, Division of General Surgery, Velletri Roma, Italy;(35)Digestive Diseases Centre CEMAD, Department of Medical and Surgical Sciences- Policlinico Universitario “A. Gemelli” Foundation- IRCCS- Rome- Italy 9 Catholic University- School of Medicine- Rome- Italy, Rome, Italy;(36)Territorial Gastroenterology Service- ASL BAT- Andria- Italy, Department of Medical and Surgical Sciences- Catholic University- School of Medicine, Andria, Italy; De Barba Caterina D'Antonio Elvira Montesano Laura Luzza Francesco Donnarumma Laura Cataletti Giovanni Pasta Andrea Serio Mariaelena Sebkova Ladislava Sedda Silvia D'Onofrio Vittorio De Luca Leonardo Kayali Stefano Di Paolo Maria Carla Cazato Alessia Immacolata Scorza Stefano Perazzo Patrizia Cassieri Claudio
P1055: Refusing Stoma-Forming Surgery: Preliminary Findings from an Interpretative Phenomenological Analysis of Patients with Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Rudnik, A.(1,2,3)*;Piotrowicz, G.(4);Synowiecka, A.(4);Piotrowicz, A.(4);Klufczyńska, A.(4);
(1)University of Gdansk, Institute of Psychology, Gdańsk, Poland;(2)Self-Dependent Health Care Unit of Ministry of Interior and Administration, Department of Gastroenterology, Gdask, Poland;(3)University of Gdansk, Academic Psychological Support Centre, Gdansk, Poland;(4)Self-Dependent Health Care Unit of Ministry of Interior and Administration, Department of Gastroenterology, Gdansk, Poland;
1. Dibley L, Czuber-Dochan W, Wade T, Duncan J, Burch J, Warusavitarne J, Norton C, Artom M, O’Sullivan L, Verjee A, Cann D. Patient decision-making about emergency and planned stoma surgery for IBD: a qualitative exploration of patient and clinician perspectives. Inflammatory Bowel Diseases. 2018;18;24(2):235-46.
2. Zhang JE, Wong FK, Zheng MC. The preoperative reaction and decision-making process regarding colostomy surgery among Chinese rectal cancer patients. European Journal of Oncology Nursing. 2017;28:107-13.
3. Clark M, Chur-Hansen A, Mikocka-Walus A. Systematic review with meta-analysis: Current and emerging models of preoperative psychological preparation for individuals undergoing stoma surgery. Journal of Psychosomatic Research. 2023;168:111211.
P1056: Effectiveness and Safety of Upadacitinib Induction Therapy in Real-World Setting for 234 Patients with Crohn's Disease: A GETAID Multicentre Cohort Study.ECCO'25Year: 2025
Authors: Richard, N.(1)*;Amiot, A.(2);Seksik, P.(3);Altwegg, R.(4);Laharie, D.(5);Vuitton, L.(6);Nachury, M.(7);Nancey, S.(8);Bouguen, G.(9);Gilletta, C.(10);Rouillon, C.(11);Coffin, B.(12);Allez, M.(13);Buisson, A.(14);Le Berre, C.(15);Pelletier, A.L.(16);Uzzan, M.(17);Caillo, L.(18);Sickersen, G.(19);Hupé, M.(20);Abitbol, V.(21);Vidon, M.(22);Goutorbe, F.(23);Amil, M.(24);Brixi, H.(25);Benezech, A.(26);Kwiatek, S.(27);Peyrin-Biroulet, L.(28);Fumery, M.(29);
(1)Univ Rouen Normandie- INSERM- ADEN UMR1073- "Nutrition- Inflammation and microbiota-gut-brain axis"- CHU Rouen, Department of Gastroenterology, F-76000 Rouen, France;(2)Hôpitaux Universitaires Bicêtre- AP-HP- Université Paris Saclay, Department of Gastroenterology, Le Kremlin Bicêtre, France;(3)CRSA- Sorbonne Université- INSERM- APHP- Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France;(4)CHU of Montpellier, Department of Gastroenterology, Montpellier, France;(5)CHU de Bordeaux- Hôpital Haut-Lévêque- Université de Bordeaux - INSERM CIC 1401, Gastroenterology department, Bordeaux, France;(6)UMR 1098- University of Franche-Comté, Department of Gastroenterology, Besançon, France;(7)Univ. Lille- Inserm- CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France;(8)CHU of Lyon, Department of Gastroenterology, Lyon, France;(9)CHU Rennes- Univ Rennes- INSERM, CIC1414- Institut NUMECAN Nutrition Metabolism and Cancer, Rennes, France;(10)CHU of Toulouse RANGUEIL, Department of Gastroenterology and Pancreatology, Toulouse, France;(11)Caen University Hospital, Department of Gastroenterology, Caen, France;(12)AP-HP Nord- Hôpital Louis Mourier-, Department of Gastroenterology, Colombes, France;(13)Hôpital Saint-Louis - APHP- Université Paris Cité- INSERM U1160, Gastroenterology Department, Paris, France;(14)Université Clermont Auvergne- 3iHP- CHU Clermont-Ferrand- Inserm U1071- M2iSH- USC-INRA 2018, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France;(15)Inserm CIC 1413- Inserm UMR 1235- Institut des Maladies de l'Appareil Digestif IMAD- Nantes Université- CHU Nantes, Hépato-Gastro-Entérologie et Assistance Nutritionnelle, Nantes, France;(16)Bichat-Claude Bernard University Hospital- APHP, Gastroenterology Department, Paris, France;(17)Henri Mondor Hospital- Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs- Paris Est Créteil University UPEC- APHP, Gastroenterology Department, Paris, France;(18)Nîmes Hospital, Gastroenterology Department, Nîmes, France;(19)Poitiers Hospital, Gastroenterology Department, Poitiers, France;(20)Univ. Grenoble Alpes / CHU Grenoble Alpes / Institute for Advanced Biosciences- CNRS UMR 5309-INSERM U1209, Hepato-Gastroenterology and Digestive Oncology department, Grenoble, France;(21)Cochin University Hospital- AP-HP- Université Paris Cité, Department of Gastroenterology, Paris, France;(22)Centre Hospitalier Inter-communal of Créteil, Gastroenterology Department, Créteil, France;(23)Gastroenterology Department, Bayonne Hospital, Bayonne, France;(24)La Roche Sur Yon Hospital, Department of Gastroenterology-, La Roche Sur Yon, France;(25)Reims University Hospital, Department of Gastroenterology, Reims, France;(26)Avignon Hospital, Department of Gastroenterology, Avignon, France;(27)Saint Pierre Ile de la Réunion University Hospital, Department of Gastroenterology, Saint Pierre, France;(28)IHU Infiny- CHRU Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;(29)Amiens University Hospital- and PeriTox- Université de Picardie, Department of Gastroenterology, Amiens, France;
1. Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2023;388(21):1966-1980.
P1057: Early use of tumour necrosis factor antagonist for treatment of paediatric Crohn’s disease decreases perianal fistula development: a post-hoc analysis of a prospective, multicentre studyECCO'25Year: 2025
Authors: Gadepalli, S.(1);Adler, J.(2)*;
(1)University of Michigan, Pediatric surgery, Ann Arbor, United States;(2)University of Michigan, Susan B. Meister Child Health Evaluation and Research Center, Ann Arbor, United States; BISCUIT study group
1. Adler J, Dong S, Eder SJ, Dombkowski KJ, ImproveCareNow Pediatric IBDLHS. Perianal Crohn Disease in a Large Multicenter Pediatric Collaborative. Journal of pediatric gastroenterology and nutrition. 2017;64:e117-e124
2. Adler J, Lin CC, Gadepalli SK, Dombkowski KJ. Association Between Steroid-Sparing Therapy and the Risk of Perianal Fistulizing Complications Among Young Patients With Crohn Disease. JAMA Netw Open. 2020;3:e207378
3. Singer AAM, Bloom DA, Adler J. Factors Associated With Development of Perianal Fistulas in Pediatric Patients With Crohn's Disease. Clinical gastroenterology and hepatology. 2021;19:1071-1073.
P1058: Trajectories of response in patients with moderately-to-severely active Crohn’s disease treated with mirikizumab based on biofailed status: Post hoc results from the VIVID-1 studyECCO'25Year: 2025
Authors: Schreiber , S.W.(1);Clemow , D.B.(2)*;Yu , G.(2);Keefer , L.A.(3);Ananthakrishnan , A.N.(4);D'Haens , G.(5);Deepak , P.(6);Kochhar , G.S.(7);Melmed , G.Y.(8);Chen , Y.F.(2);Moses , R.E.(2);
(1)University Hospital Schleswig-Holstein- Christian-Albrecht University of Kiel, Department of Internal Medicine, Kiel, Germany;(2)Eli Lilly and Company, Lilly Immunology, Indianapolis, United States;(3)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(4)Massachusetts General Hospital and Harvard Medical School, Division of Gastroenterology, Boston, United States;(5)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)Washington University in St. Louis School of Medicine, Division of Gastroenterology, St. Louis, United States;(7)Allegheny Health Network, Division of Gastroenterology- Hepatology- and Nutrition, Pittsburgh, United States;(8)Cedars Sinai Medical Center, Karsh Division of Gastroenterology, Los Angeles, United States;
1. M Ferrante, S Danese, M Chen, et al. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study, Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024., Pages i7–i9, https://doi.org/10.1093/ecco-jcc/jjad212.0005.
P1059: Fecal calprotectin response to Tasty&Healthy dietary intervention in asymptomatic children and young adults with biologically active Crohn's disease: results of the "TASTI-E" randomized controlled trialECCO'25Year: 2025
Authors: Plotkin, L.(1,2)*;Aharoni Frutkoff, Y.(1);Shavit, Z.(1);Focht, G.(1);Buchuk, R.(3);Lev-Zion, R.(1);Sigall Boneh, R.(4); Weiss, B.(5);Slae, M.(6);Dotan, I.(7);Godny, L.(7);Kierkuś, J.(8);Matuszczyk, M.(8);Broide, E.(9);Moshe, G.(9);Griffiths, A.(10);Martincevic, I.(10);Naftali, T.(11);Abramas, L.(11);Aloi, M.(12);Mercurio, R.(12);Yerushalmy-Feler, A.(13);Schwerd, T.(14);Crowley, E.(15);Reifen, R.(16);Turner, D.(1);
(1)Shaare Zedek Medical Center, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)The Hebrew University of Jerusalem, Institute of Biochemistry- Food Science and Nutrition Robert H. Smith Faculty of Agriculture- Food and Environment, Re, Israel;(3)Shaare Zedek Medical Center, he Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(4)The E. Wolfson Medical Center, Pediatric Gastroenterology and Nutrition Unit, Holon, Israel;(5)Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel;(6)Hadassah Ein Kerem, The Pediatric Gastroenterology Center, Jerusalem, Israel;(7)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(8)Children’s Memorial Health Institute, Pediatric Gastroenterology Unit, Warsaw, Poland;(9)Assaf Harofeh Medical Center, Pediatric Gastroenterology Unit, Zerifin, Israel;(10)Hospital for Sick Children, Pediatric Gastroenterology, Toronto, Canada;(11)Meir Hospital, Gastroenterology, Kfar Saba, Israel;(12)Sapienza University of Rome, Dept. of Pediatric Gastroenterology, Rome, Italy;(13)Tel Aviv Sourasky Medical Center, Pediatric Gastroenterology, Tel Aviv, Israel;(14)LMU München, Dr von Hauner Children`s Hospital-, Munich, Germany;(15)The Research Institute of London Health Sciences Centre and St. Joseph's Health Care, Pediatric Gastroenterology, London, Canada;(16)The Hebrew University of Jerusalem, Institute of Biochemistry- Food Science and Nutrition Robert H. Smith Faculty of Agriculture- Food and Environment, Rehovot, Israel;
P1060: Exploring The Relationship Between Hormonal Contraceptive Use And Ulcerative Colitis Flares: A Longitudinal AnalysisECCO'25Year: 2025
Authors: Frutos, C.(1);Benítez, J.M.(1);Soto, P.(1);Marín Pedrosa, S.(1);Iglesias-Flores, E.(1);Gros, B.(2)*;
(1)Reina Sofía University Hospital, Gastroenterology and Hepatology, Cordoba, Spain;(2)Reina Sofía University Hospital. IMIBIC. University of Cordoba., Gastroenterology and Hepatology, Córdoba, Spain;
P1061: A matching-adjusted indirect comparison (MAIC) of vedolizumab vs risankizumab in patients with moderately-to-severely active Crohn’s diseaseECCO'25Year: 2025
Authors: Jairath, V.(1)*;Dulai, P.S.(2);Talsma, P.(3);Wu, J.J.(3);Adsul, S.(3);
(1)Western Univesity- Alimentiv, Schulich School of Medicine & Dentistry, London- ON, Canada;(2)Northwestern Medical Group, Medical, Chicago- IL, United States;(3)Takeda Pharmaceuticals, Global Medical Affairs, Cambridge- MA, United States;
1. D’Haens G, et al. Lancet. 2022;399(10340):2015-2030. 2. Ferrante M, et al. Lancet. 2022;399(10340):2031-2046. 3. Sandborn W.J, et al. N Engl J Med. 2013;369(8):711-721. 4. Vermeire S, et al. J Crohns Colitis. 2022;16(1):27-38.
P1062: Microbially Conjugated Bile Acids as Potential Predictive Biomarkers for Dietary Therapy Outcomes in Paediatric Crohn’s DiseaseECCO'25Year: 2025
Authors: Van Der Kruk, N.(1,2,3)*;de Haas, I.M.(4);Ghiboub, M.(1,3,5);de Waart, D.R.(3);Sigall Boneh, R.(3,6);de Meij, T.G.J.(1);Wine, E.(7);de Jonge, W.J.(3,8);D'Haens, G.R.A.M.(3,9);van de Graaf, S.F.J.(3);van Limbergen, J.E.(1,3);
(1)Amsterdam UMC, Department of Paediatric Gastroenterology and Nutrition- Emma Children's Hospital, Amsterdam, The Netherlands;(2)Amsterdam UMC, Amsterdam Reproduction and Development research institute, Amsterdam, The Netherlands;(3)Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology- Endocrinology Metabolism AGEM- Amsterdam UMC- University of Amsterdam, Amsterdam, The Netherlands;(4)Faculty of Medicine- University of Amsterdam UvA, Biomedical Sciences, Amsterdam, The Netherlands;(5)Amsterdam UMC- University of Amsterdam, Department of Paediatric Surgery- Emma Children's Hospital, Amsterdam, The Netherlands;(6)The E. Wolfson Medical Center, Paediatric Gastroenterology and Nutrition Unit-, Holon, Israel;(7)University of Alberta, Department of Pediatrics, Edmonton- Alberta, Canada;(8)University clinic of Bonn, Dept of Surgery, Bonn, Germany;(9)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
1. Verburgt CM, Dunn KA, Ghiboub M, et al. Successful Dietary Therapy in Paediatric Crohn's Disease is Associated with Shifts in Bacterial Dysbiosis and Inflammatory Metabotype Towards Healthy Controls. J Crohns Colitis. Jan 27 2023;17(1):61-72. doi:10.1093/ecco-jcc/jjac105
2. Quinn RA, Melnik AV, Vrbanac A, et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020/03/01 2020;579(7797):123-129. doi:10.1038/s41586-020-2047-9
3. Levine A, Wine E, Assa A, et al. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology. Aug 2019;157(2):440-450.e8. doi:10.1053/j.gastro.2019.04.021
P1063: Impact of Upadacitinib in Crohn's Disease in the Medium Term: Results from the UPITA-Crohn Registry in Clinical Practice.ECCO'25Year: 2025
Authors: Caballero Mateos, A.M.(1)*;Lázaro-Sáez, M.(2);Hernández-Martínez, Á.(2);Rodríguez-González, F.J.(3);González-Parra, A.C.(4);Martín-Rodríguez, M.D.M.(5);Agulleiro-Beraza, I.(6);Gijón-Villanova, R.(7);Saldaña, L.(8);Trapero-Martínez, A.M.(9);Gómez-Delgado, E.(10);Benítez, J.M.(11);Olmedo-Martín, R.V.(12);
(1)Santa Ana Hospital, Gastroenterology, Granada, Spain;(2)Torrecárdenas University Hospital, Gastroenterology, Almería, Spain;(3)Virgen de la Victoria Hospital, Gastroenterology, Granada, Spain;(4)Virgen Macarena University Hospital, Gastroenterology, Seville, Spain;(5)Virgen de las Nieves University Hospital, Gastroenterology, Granada, Spain;(6)Virgen del Rocío University Hospital, Gastroenterology, Seville, Spain;(7)San Cecilio University Hospital, Gastroenterology, Granada, Spain;(8)Costa del sol Hospital, Gastroenterology, Marbella, Spain;(9)University Hospital of Jaén, Gastroenterology, Jaén, Spain;(10)Juan Ramón Jiménez Hospital, Gastroenterology, Huelva, Spain;(11)Reina Sofía University Hospital, Gastroenterology, Córdoba, Spain;(12)Regional University Hospital, Gastroenterology, Málaga, Spain; GATEII
- Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014; 57: 5023–38.
- Padda IS, Bhatt R, Parmar M. Upadacitinib. 2023 Jun 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 34283454.
- Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, D'Haens G, Panaccione R, Reinisch W, Louis E, Chen M, Nakase H, Begun J, Boland BS, Phillips C, Mohamed MF, Liu J, Geng Z, Feng T, Dubcenco E, Colombel JF. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2023 May 25;388(21):1966-1980. doi: 10.1056/NEJMoa2212728.
P1064: Association of subcutaneous infliximab CT-P13 serum levels and therapeutic outcomes in patients affected by Inflammatory Bowel Disease: A retrospective international multicentric studyECCO'25Year: 2025
Authors: Centritto, A.(1)*;Samaan, M.(2);Ward, M.(3);Van Wees, J.(3);Outtier, A.(4);Ferrante, M.(4);Novak, G.(5);Šubic, Ž.(6);Papamichail, K.(7);Irving, P.M.(8);
(1)Guy's and St. Thomas' NHS foundation trust, Gastroenterology, London, United Kingdom;(2)Guys and St. Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(3)Alfred Health, Department of Gastroenterology, Melbourne, Australia;(4)University Hospitals Leuven - KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;(6)University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia;(7)Beth-Israel Deaconess Medical Center - Harvard Medical School, Center for Inflammatory Bowel Diseases- Division of Gastroenterology-, Boston, United States;(8)Guy's and St. Thomas' NHS Foundation Trust-, Department of Gastroenterology, London, United Kingdom; spECTRUM
Roblin X, Nancey S, Papamichael K, et al. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2024;18(5):679-685. doi:10.1093/ecco-jcc/jjad188Iborra M, Caballol B, Garrido A, et al. Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry. J Crohns Colitis. Published online August 22, 2024. doi:10.1093/ecco-jcc/jjae127
P1065: Rapid onset of action of ustekinumab in patients with moderate to severe Ulcerative Colitis (RAUCU Study)ECCO'25Year: 2025
Authors: Bastón Rey, I.(1)*;García Alvarado, M.(2);García Morales, N.(3);Fernández Suárez, B.(4);Latras-Cortés, I.(5);Ferreiro-Iglesias, R.(1);Santos Fernández, J.(6);Tejido Sandoval, C.(7);Vázquez Rey, M.T.(8);García Alonso, F.J.(9);Guerrero Montañés, A.(10);Molina Arriero, G.(11);Velayos Jimenez, B.(12);Ruíz Barcia, M.J.(13);Ibáñez García, M.(14);Porto Silva, M.S.(1);Tejerizo García, L.(2);Ucha Abal, P.(3);Martí Marqués, E.(4);Nieto García, L.(1);Gómez Hidalgo, R.(2);Muñoz Núñez, F.(2);Barreiro-de Acosta, M.(1);
(1)University Hospital of Santiago De Compostela CHUS and Health Research Institute of Santiago de Compostela IDIS, Gastroenterology, Santiago De Compostela, Spain;(2)University Hospital of Salamanca, Gastroenterology, Salamanca, Spain;(3)University Hospital of Vigo CHUVI and Galicia Sur Health Research Institute ISS Galicia Sur, Gastroenterology, Vigo, Spain;(4)University Hospital Lucus Augusti, Gastroenterology, Lugo, Spain;(5)University Hospital of León, Gastroenterology, León, Spain;(6)Hospital Río Carrión, Gastroenterology, Palencia, Spain;(7)University Hospital of Ourense CHOU, Gastroenterology, Ourense, Spain;(8)University Hospital of A Coruña CHUAC, Gastroenterology, A Coruña, Spain;(9)University Hospital Río Hortega, Gastroenterology, Valladolid, Spain;(10)Hospital Virxe da Xunqueira, Gastroenterology, Cee, Spain;(11)University Hospital of Ferrol CHUF, Gastroenterology, Ferrol, Spain;(12)University Hospital of Valladolid HCUV, Gastroenterology, Valladolid, Spain;(13)Hospital da Costa, Gastroenterology, Burela, Spain;(14)Hospital Medina del Campo, Gastroenterology, Valladolid, Spain;
P1066: Effectiveness and safety of vedolizumab in real-world studies in Asian patients with inflammatory bowel disease: a systematic review and meta-analysisECCO'25Year: 2025
Authors: Gu, Y.(1)*;Zhang, X.(2);Gu, L.(2);Zou, D.(1);
(1)Ruijin Hospital- Shanghai Jiao Tong University School of Medicine, Department of Gastroenterology, Shanghai, China;(2)Takeda China International Trading Co.- Ltd., Medical affairs, Shanghai, China;
P1067: Comparison of AZA-Related Pancreatitis and AZA-Related GI Intolerance Based on Demographic Factors, Clinical Variables and HLA DQA1/DRB1 AllelesECCO'25Year: 2025
Authors: Eskazan, T.(1)*;Bakkaloğlu, O.K.(1);Toruner, M.(2);Kani, H.T.(3);Cavus, B.(4);Yılmaz, V.(2);Ünal, N.G.(5);Akyüz, F.(4);Atuğ, Ö.(3);Hatemi, A.İ.(1);Yılmaz, E.(6);Dogruel, M.(6);Erzin, Y.(1);Çelik, A.F.(1);
(1)İstanbul University-Cerrahpaşa- Cerrahpaşa Faculty of Medicine, Department of Internal Medicine- Division of Gastroenterology, Istanbul, Turkey;(2)Ankara University Faculty of Medicine, Department of Internal Medicine- Division of Gastroenterology, Ankara, Turkey;(3)Marmara University Faculty of Medicine, Department of Internal Medicine- Division of Gastroenterology, Istanbul, Turkey;(4)İstanbul University Faculty of Medicine, Department of Internal Medicine- Division of Gastroenterology, Istanbul, Turkey;(5)Ege University Faculty of Medicine, Department of Internal Medicine- Division of Gastroenterology, İzmir, Turkey;(6)İstanbul University-Cerrahpaşa- Cerrahpaşa Faculty of Medicine, HLA Laboratory, Istanbul, Turkey;
1.Teich N, Mohl W, Bokemeyer B, et al. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity. J Crohns Colitis. 2016;10(1):61-68. doi:10.1093/ecco-jcc/jjv188
2.Eskazan T, Bozcan S, Atay K, et al. Frequency, Predisposing Factors, and Clinical Outcome of Azathioprine-Induced Pancreatitis Among Patients With Inflammatory Bowel Disease: Results From a Tertiary Referral Center. Pancreas. 2021;50(9):1274-1280. doi:10.1097/MPA.0000000000001914
3.Wilson A, Wang Q, Choi YH, et al. Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study. Clin Transl Gastroenterol. 2021;12(4):e00332. Published 2021 Apr 5. doi:10.14309/ctg.0000000000000332
4.Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014;46(10):1131-1134. doi:10.1038/ng.3093
